Mylan NV (NASDAQ:MYL)

72.89
Delayed Data
As of May 05
 -0.16 / -0.22%
Today’s Change
44.80
Today|||52-Week Range
76.69
+29.31%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Generic
MARKET CAP
$35.8B

Company Description

Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products. It operates through the following businesses: Generic Products, Rx Products, Active Pharmaceutical Ingredients, and Access Channels. The Generic Products business provides therapeutic categories, dosage forms and delivery system to help patients. The Rx Products business develops, manufacture and sells prescription medicines to help patients and physicians manage respiratory diseases, severe allergic reactions and psychiatric disorders. The Active Pharmaceutical Ingredients business produces API, the ingredients responsible for medicine's therapeutic effects, and antiretrovirals, the medicines for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). The Access Channels business provides access to medicines. The company was founded on July 7, 2014 and is headquartered in Potters Bar, United Kingdom.

Contact Information

Mylan NV
Albany Gate
Potters Bar Hertfordshire EN6 1AG
P:441707853000
Investor Relations:
(724) 514-1831

Employees

Shareholders

Other institutional42.20%
Mutual fund holders34.39%
Individual stakeholders14.71%

Top Executives

Heather M. BreschChief Executive Officer & Executive Director
Rajiv MalikPresident & Executive Director
John D. SheehanExecutive VP, Chief Financial & Accounting Officer
Kris KingVice President-Global Investor Relations

To view my watchlist

Not a member yet?

Sign up now for a free account